OnabotA for OAB: Enhancing comfort and ensuring adherence

A recently published paper sought to outline best practices in the treatment of overactive bladder (OAB) using onabotulinumtoxinA (onabotA, Botox).¹

In a recent interview with Urology Times®,study author Karyn S. Eilber, MD, emphasized the critical role of the procedure room environment and follow-up protocols in optimizing patient comfort and adherence to overactive bladder (OAB) management with onabotulinumtoxinA (Botox) injections.

To enhance patient experience and encourage return visits, Eilber's office implements several strategies. These include using aromatherapy machines with soft lights instead of harsh fluorescent lighting and offering background noise options. They provide cloth gowns for comfort and encourage patients to wear warm clothing. The presence of consistent staff and the use of "verbal anesthesia" also contribute significantly to a more positive experience, even when the procedure itself might be physically uncomfortable.

EP: 1.Optimizing onabotA for OAB: What are some common misconceptions?

EP: 2.Karyn S. Eilber, MD, on patient counseling for onabotA treatment for OAB

EP: 3.Administering onabotA: Improving patient comfort and easing anxiety

EP: 4.Considerations for patient follow-up after onabotA administration

Now Viewing

EP: 5.OnabotA for OAB: Enhancing comfort and ensuring adherence

EP: 6.From prep to follow-up: Key considerations for administering onabotulinumtoxinA

Regarding follow-up, Eilber's protocol involves a 2-week post-injection check-up to assess residual urine and the efficacy of the onabotA. Subsequent injections are typically scheduled at 6-month intervals, aligning with the average duration of effect. However, patients are advised to adjust this schedule based on their individual response, ranging from 5-month intervals if the effect wears off sooner, to potentially 7 or 8 months if the benefits last longer. The importance of proactively scheduling the next appointment was highlighted to prevent lapses in treatment, ensuring ongoing therapy and reducing logistical barriers for both patients and the practice.

REFERENCE

1. Eilber KS, Brucker BM, Pezzella A, Lucente V, Benson K, Kennelly MJ. Expert opinions on best practices for overactive bladder management with onabotulinumtoxinA. Toxins (Basel). 2025;17(4):207. doi:10.3390/toxins17040207